Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Hexarelin | KPV | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 100-200 mcg administered 1-2 times daily via subcutaneous injection. | Research indicates 200-500 mcg daily via subcutaneous injection, or 500 mcg-1 mg orally for gut-targeted inflammation. |
| Timing | On empty stomach, bedtime preferred. Avoid prolonged continuous use due to rapid desensitization. | Oral dosing on empty stomach for gut-targeted effects. No strict timing for subcutaneous. |
| Cycle Duration | 4-8 week cycles maximum, then 4+ week break. Hexarelin desensitizes faster than other GHRPs. | 4-12 weeks. Oral protocols for gut inflammation may extend longer under supervision. |
| Evidence Level | moderate_human | animal_plus_anecdotal |
Hexarelin (Examorelin) is a synthetic hexapeptide GHS-R1a agonist and the most potent synthetic GH secretagogue by peak GH release. It stimulates GH release through both pituitary ghrelin receptors and hypothalamic pathways, with mechanisms involving regulation of GHRH and somatostatin. Hexarelin also demonstrates significant cardiac benefits through activation of cardiac GHS-R1a receptors, protecting against ischemia-reperfusion injury and reducing cardiac fibrosis via the CD36 scavenger receptor pathway.
Research indicates 100-200 mcg administered 1-2 times daily via subcutaneous injection.
On empty stomach, bedtime preferred. Avoid prolonged continuous use due to rapid desensitization.
4-8 week cycles maximum, then 4+ week break. Hexarelin desensitizes faster than other GHRPs.
KPV (Lysine-Proline-Valine) is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH) that inhibits NF-kB signaling through a non-melanocortin receptor-mediated mechanism. It is transported intracellularly via the PepT1 transporter, where it stabilizes IkB-alpha and suppresses nuclear translocation of p65RelA by competing with importin-beta at the armadillo domain 7 and 8 binding site. It also reduces MAPK inflammatory signaling and IL-8 secretion in intestinal epithelial cells.
Research indicates 200-500 mcg daily via subcutaneous injection, or 500 mcg-1 mg orally for gut-targeted inflammation.
Oral dosing on empty stomach for gut-targeted effects. No strict timing for subcutaneous.
4-12 weeks. Oral protocols for gut inflammation may extend longer under supervision.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →